Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

Exclusion Criteria

• •Known history of RVFV infection
• •Previous receipt of RVFV vaccine
• •Illness with fever within 5 days prior to administration
• •History of malignancy within prior 5 years
• •History of significant cardiovascular, pulmonary, gastrointestinal, liver, kidney, hematologic, neurological, psychiatric, endocrine, immunologic, dermatologic disease
• •History of hypersensitivity reaction
• •History or clinical evidence of alcohol abuse
• •Human immunodeficiency virus (HIV) positive
• •Hepatitis C virus positive
• •Hepatitis B virus positive
• •Received immunoglobulin or antibody product within 6 months of administration
• •Vaccine within 28 days of administration
• •Received investigational agent within 3 months or \< 5 half-lives (whichever is longer) prior to administration
• •Donation of plasma, 1 unit or \> 500 mL blood donation in 56 days prior to administration